Cargando…

Safety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review

Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) allows radical resection of colorectal liver metastasis (CRLM). However, the effect of ALPPS on hepatocellular carcinoma (HCC) is not completely understood. This systematic review aimed to examine the existing data o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Junwei, Huang, Hanchun, Bian, Jin, Sang, Xinting, Xu, Yiyao, Lu, Xin, Zhao, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607135/
https://www.ncbi.nlm.nih.gov/pubmed/33178778
http://dx.doi.org/10.21037/atm-20-2214
_version_ 1783604584147582976
author Zhang, Junwei
Huang, Hanchun
Bian, Jin
Sang, Xinting
Xu, Yiyao
Lu, Xin
Zhao, Haitao
author_facet Zhang, Junwei
Huang, Hanchun
Bian, Jin
Sang, Xinting
Xu, Yiyao
Lu, Xin
Zhao, Haitao
author_sort Zhang, Junwei
collection PubMed
description Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) allows radical resection of colorectal liver metastasis (CRLM). However, the effect of ALPPS on hepatocellular carcinoma (HCC) is not completely understood. This systematic review aimed to examine the existing data on the safety, feasibility, and oncologic effect of ALPPS on HCC. Electronic databases, including PubMed, Web of Science, and Embase, were systemically searched to identify articles on ALPPS and HCC. Additional articles were identified manually. The feasibility (liver hypertrophy between two stages), safety (90-day mortality), and therapeutic effect (long-term survival) were analyzed. Nine published articles that satisfied the retrieval standards were included, and these studies involved 176 patients. The evidence level of the enrolled studies was low, among which, the greatest Oxford evidence level was 2c. Additionally, the average median increase in future liver volume was 178 mL, the average interval between two stages was 11.2 days, the interval was remarkably longer in radiofrequency-assisted ALPPS (RALPPS) patients (28 days), and the average 90-day mortality was 17.6% (range, 0–50%). However, the oncological outcomes were not well documented. Survival following ALPPS was evidently improved compared with that after transcatheter arterial chemoembolization (TACE). This value was comparable to that following the one-stage hepatectomy and portal vein embolization (PVE), and it was similar to that in CRLM patients over the long term. Publication biases caused by case series and single-center reports are common in the review. It is concluded in this review that ALPPS is a safe and feasible approach to treat selected patients with unresectable HCC, but its oncological outcome requires further study. RALPPS is not recommended for HCC patients because of the long waiting time between the two stages.
format Online
Article
Text
id pubmed-7607135
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-76071352020-11-10 Safety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review Zhang, Junwei Huang, Hanchun Bian, Jin Sang, Xinting Xu, Yiyao Lu, Xin Zhao, Haitao Ann Transl Med Review Article Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) allows radical resection of colorectal liver metastasis (CRLM). However, the effect of ALPPS on hepatocellular carcinoma (HCC) is not completely understood. This systematic review aimed to examine the existing data on the safety, feasibility, and oncologic effect of ALPPS on HCC. Electronic databases, including PubMed, Web of Science, and Embase, were systemically searched to identify articles on ALPPS and HCC. Additional articles were identified manually. The feasibility (liver hypertrophy between two stages), safety (90-day mortality), and therapeutic effect (long-term survival) were analyzed. Nine published articles that satisfied the retrieval standards were included, and these studies involved 176 patients. The evidence level of the enrolled studies was low, among which, the greatest Oxford evidence level was 2c. Additionally, the average median increase in future liver volume was 178 mL, the average interval between two stages was 11.2 days, the interval was remarkably longer in radiofrequency-assisted ALPPS (RALPPS) patients (28 days), and the average 90-day mortality was 17.6% (range, 0–50%). However, the oncological outcomes were not well documented. Survival following ALPPS was evidently improved compared with that after transcatheter arterial chemoembolization (TACE). This value was comparable to that following the one-stage hepatectomy and portal vein embolization (PVE), and it was similar to that in CRLM patients over the long term. Publication biases caused by case series and single-center reports are common in the review. It is concluded in this review that ALPPS is a safe and feasible approach to treat selected patients with unresectable HCC, but its oncological outcome requires further study. RALPPS is not recommended for HCC patients because of the long waiting time between the two stages. AME Publishing Company 2020-10 /pmc/articles/PMC7607135/ /pubmed/33178778 http://dx.doi.org/10.21037/atm-20-2214 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article
Zhang, Junwei
Huang, Hanchun
Bian, Jin
Sang, Xinting
Xu, Yiyao
Lu, Xin
Zhao, Haitao
Safety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review
title Safety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review
title_full Safety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review
title_fullStr Safety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review
title_full_unstemmed Safety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review
title_short Safety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review
title_sort safety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607135/
https://www.ncbi.nlm.nih.gov/pubmed/33178778
http://dx.doi.org/10.21037/atm-20-2214
work_keys_str_mv AT zhangjunwei safetyfeasibilityandefficacyofassociatingliverpartitionandportalveinligationforstagedhepatectomyintreatinghepatocellularcarcinomaasystematicreview
AT huanghanchun safetyfeasibilityandefficacyofassociatingliverpartitionandportalveinligationforstagedhepatectomyintreatinghepatocellularcarcinomaasystematicreview
AT bianjin safetyfeasibilityandefficacyofassociatingliverpartitionandportalveinligationforstagedhepatectomyintreatinghepatocellularcarcinomaasystematicreview
AT sangxinting safetyfeasibilityandefficacyofassociatingliverpartitionandportalveinligationforstagedhepatectomyintreatinghepatocellularcarcinomaasystematicreview
AT xuyiyao safetyfeasibilityandefficacyofassociatingliverpartitionandportalveinligationforstagedhepatectomyintreatinghepatocellularcarcinomaasystematicreview
AT luxin safetyfeasibilityandefficacyofassociatingliverpartitionandportalveinligationforstagedhepatectomyintreatinghepatocellularcarcinomaasystematicreview
AT zhaohaitao safetyfeasibilityandefficacyofassociatingliverpartitionandportalveinligationforstagedhepatectomyintreatinghepatocellularcarcinomaasystematicreview